Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
23.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (9.091%)
Market Cap: £24.84m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading update

1 Feb 2013 07:00

RNS Number : 8726W
Elektron Technology PLC
01 February 2013
Β 

ο»Ώ

1 February 2013

Β 

Elektron Technology plcΒ 

Β 

Year-end technology, trading and operations update

Β 

Elektron Technology plc (AIM: EKT, "Elektron" or the "Group"), the global technology group, provides an update on performance for the full year to 31 January 2013.

Β 

Elektron continues to make significant progress in building its new product development pipeline and in developing an organisation that is fit for the future. This multi-year transformation agenda is designed to create an innovation led technology company with a world class infrastructure and a portfolio of products with unique selling points, protected through intellectual property rights. Sales from continuing operations in the year were approximately Β£55m (2012: Β£63m); further information is provided under Trading and outlook below.

Β 

New product development ('NPD') in 2012/13

Β 

Following the foundation of its Technology Centre in Cambridge in mid 2011, Elektron has made its first significant new product launches for many years. This development is much needed, as the Group's legacy product portfolio is mature in its life cycle, naturally leading to a reduction in demand for some products. In Connectivity, for example, over 75% of the core range is now more than 30 years old and the portfolio in Instrumentation, Monitoring and Control is also in need of renewal.

Β 

New products were introduced across three separate product lines during the year:

Β 

Ø The Bulgin 6000 series twist and lock (patent pending) connectors for harsh environments

Β 

Ø The first line in a new range of Queensgate nanopositioning products with Dual Sensor Control technology (patent pending)

Β 

Ø The MPS II ophthalmic device for age related macular degeneration ("AMD") screening under the Elektron Technology brand. This is the only such instrument available worldwide in its price range.

Β 

Each of these new products has been well received in its relevant market, though sales pipelines naturally take time to build. In the case of medical products it is necessary to gain approval from government regulatory agencies prior to selling in most geographical markets. With lessons learned from these developments, the Group continues to invest in NPD with confidence.

Β 

Planned launches in 2013/14

Β 

The pace of investment increased substantially in the year just ended and further significant new product introductions are planned for 2013/14. Elektron intends to launch the following in the current year:

Β 

Ø Further extensions to the Bulgin range of connectors for harsh environments

Β 

Ø Additions to Queensgate nanopositioning products

Β 

Ø Elektron's first product involving a platform technology addressing the "Internet of Things", a system of smart sensors, wireless communications and networked computing that transforms how innovative solutions can be built and delivered.

Β 

Product line rationalisation

Β 

Elektron views the diversity of its product range as a strength. However, parts of the portfolio are of low, no or negative growth. A managed cull of underperforming brands and products has begun, to ensure that investment is focussed on areas with the most potential for profits and growth. The ASL brand, one of the smallest brands acquired with the Hartest business, was sold in January 2013 as part of this programme, as previously reported, and the Tinsley name is being discontinued.

Β 

Building an effective organisation

Β 

Elektron continues to make good progress in building an organisation designed to support its growth aspirations. Since the relocation of the Group to Cambridge, the senior management team has been strengthened with expert additions to key functions: Sales, Marketing, Product Line Management, Quality, Operations, Finance and Human Resources, in addition to the creation of a highly skilled technical team.

Β 

Two years ago, the Group used 11 different IT systems across its businesses for transaction processing and reporting. Today, approximately 80% of the Group's operations are managed through a single Enterprise Resource Planning system and the migration of the remaining activities onto this platform will complete during the coming year. This has brought considerable benefits in the speed, consistency and quality of information available, as well as improvements in efficiency and control.

Β 

Streamlining and cost reduction

Β 

The closure of the Redhill and West Molesey factories, announced a year ago, is on track for completion as scheduled during 2013/14 and the consolidation of Arcolectric production into the Group's facility in Tunisia is now virtually complete, with a corresponding reduction in Elektron's manufacturing activities in China which is no longer regarded by the Group as a low cost location. China remains an important market for Elektron products and the Group retains a significant presence there.

Β 

Building on the success of these changes, further rationalisation programmes have now been identified for implementation during 2013/14. Approximately Β£1.5m was invested in organisational changes during 2012/13 and the Group expects to incur a further Β£2.5m to complete these programmes in the coming year. In steady state, the programmes in aggregate are expected to deliver annual savings in excess of Β£3m, including at least Β£1m in 2013/14. In addition to the cost savings, the Group will benefit through a simplified operating configuration providing closer control of product quality and lead-time to customers.

Β 

Geographical focus

Β 

The Group has continued to focus on the creation and strengthening of selling channels in both its core and emerging markets. Through its branded manufactured products with a unique selling proposition sales have begun to stabilise, especially in the Asia Pacific region. The distribution network in this region has been further expanded to include key territories such as South Korea, Japan and Taiwan.

Β 

The Group is also seeing opportunities for its differentiated products in India. However, its legacy

Indian factored business, offering turnkey calibration and instrumentation equipment with little differentiation, has seen a dramatic decline due to local competition and falling demand. The Group is actively looking at the future of this business.

Β 

Trading and outlook

Β 

Elektron's products are on relatively short lead times, so the order book provides very limited visibility of future sales. The Group saw a modest upturn in performance in the third quarter of the year compared with the equivalent periods in the previous year, but this was not sustained to the year end. Sales in December and January were particularly disappointing.

Β 

Full year sales from continuing operations in the year to 31 January 2013 were approximately Β£55m (2012: Β£63m). Elektron remains highly operationally geared, so the decline in sales has a disproportionate effect on trading profits. As a result, it is expected that the Group's performance was around break-even in the second half of the year before interest and exceptional charges (2012: Β£1.5m).

Β 

Net borrowings at 31 January 2013 are expected to be less than Β£6m (2012: Β£4.4m), reflecting the investment in restructuring and new product development.

Β 

It will take some time for the results of the new product development programme to outweigh the effect of the economic cycle on the Group's legacy product portfolio. We therefore expect a further reduction in sales from continuing operations in the coming year. However, with a pipeline of NPD activities, continuing investment in recruiting a high calibre management team and further cost savings through streamlining Elektron faces the future with confidence.

Β 

Elektron expects to release its full year results on 11 April 2013.

Β 

Elektron Technology www.elektron-technology.com

+44 (0)1223 371 000

Keith Daley - Chairman

John Wilson - Chief Executive Officer

Noah Franklin - Chief Financial Officer

finnCap

+44 (0)20 7220 0500

Ed Frisby/ Rose Herbert - Corporate Finance

Simon Starr/Victoria Bates - Corporate Broking

College Hill

+44 (0)20 7457 2020

Adrian Duffield/Rozi Morris

Β 

Β 

Notes to Editors

Β 

Elektron Technology is a global designer and manufacturer of fast moving engineered products, the precision engineered components that enable three of the most important technology areas of the always-on, networked economy: Monitoring & Control, Connectivity and Precision Instrumentation.

Β 

The Group has a broad portfolio of products that are recognised leaders in their markets, playing a critical role in many industries from underwater construction to food preparation, semiconductor manufacture to emergency vehicle systems. They result from a commercially focused, customer-led new product development process centred on the Group's Technology Centre based in Cambridge. The Group's products are sold worldwide to 7,000 customers; 100,000 end-users, and used in all 7 continents and in space.

Β 

Elektron Technology is headquartered in Cambridge and traded on the AIM market of the London Stock Exchange.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTSDWEFFFDSEIF
Date   Source Headline
23rd Aug 20114:53 pmRNSDirector/PDMR Shareholding
23rd Aug 20114:46 pmRNSHolding(s) in Company
12th Aug 20117:00 amRNSIssue of Scrip Dividend Shares
29th Jul 20113:01 pmRNSDirector/PDMR Shareholding
29th Jul 20117:01 amRNSAppointment of Chief Financial Officer
29th Jul 20117:00 amRNSResult of AGM and Change of Name
28th Jul 20117:00 amRNSTrading Update
12th Jul 20115:02 pmRNSHolding(s) in Company
30th Jun 20114:58 pmRNSDoc re. Company's Scrip Dividend Scheme
28th Jun 20113:36 pmRNSAnnual Financial Report and Notice of AGM
16th Jun 20111:43 pmRNSHolding(s) in Company
19th May 201110:32 amRNSHolding(s) in Company
16th May 201112:03 pmRNSDirector/PDMR Shareholding
12th May 20117:00 amRNSPreliminary Results
12th Apr 20117:00 amRNSTechnology Update
10th Mar 20117:00 amRNSPre-Close Trading Update
1st Feb 20117:00 amRNSDirector/PDMR Shareholding
31st Jan 201110:24 amRNSDirector/PDMR Shareholding
20th Jan 20119:51 amRNSDirector/PDMR Shareholding and Total Voting Rights
13th Jan 20117:00 amRNSIssue of Equity
17th Dec 20107:00 amRNSTrading Statement
14th Dec 20108:42 amRNSHolding(s) in Company
2nd Dec 20107:00 amRNSHolding(s) in Company
15th Nov 20102:26 pmRNSDirectorate Change
9th Nov 20103:27 pmRNSHolding(s) in Company
5th Nov 20102:24 pmRNSHolding(s) in Company
5th Nov 20107:00 amRNSHolding(s) in Company
4th Nov 20107:00 amRNSDirector/PDMR Shareholding
1st Nov 20104:59 pmRNSHolding(s) in Company
27th Oct 201010:47 amRNSDirector/PDMR Shareholding
27th Oct 201010:47 amRNSDirector/PDMR Shareholding
5th Oct 20103:47 pmRNSDirector/PDMR Shareholding
27th Sep 20102:26 pmRNSDirector/PDMR Shareholding
24th Sep 20107:00 amRNSCompulsory Acquisition Procedure
23rd Sep 20104:32 pmRNSIssue of Equity
17th Sep 20107:00 amRNSIssue of Equity
16th Sep 20104:42 pmRNSHolding(s) in Company
16th Sep 20107:00 amRNSHalf Yearly Report
15th Sep 20101:54 pmRNSDirectorate Change
15th Sep 20107:15 amPRNProposed Cancellation from AIM Close of Offer
15th Sep 20107:00 amRNSOffer Update: Close of Offer
8th Sep 20107:00 amRNSNotification of Interim Results
24th Aug 201011:11 amRNSOffer Document Posted
12th Aug 201012:37 pmRNSDirectorate Change
6th Aug 20102:30 pmRNSDirector/PDMR Shareholding
6th Aug 20102:29 pmRNSHolding(s) in Company
6th Aug 20107:00 amRNSDirectorate Change
6th Aug 20107:00 amRNSHolding(s) in Company
5th Aug 20109:56 amRNSIssue of Equity
2nd Aug 20101:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.